140 related articles for article (PubMed ID: 21963444)
1. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder.
Lau AA; Rozaklis T; Ibanes S; Luck AJ; Beard H; Hassiotis S; Mazouni K; Hopwood JJ; Kremer EJ; Hemsley KM
Gene; 2012 Jan; 491(1):53-7. PubMed ID: 21963444
[TBL] [Abstract][Full Text] [Related]
2. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
[TBL] [Abstract][Full Text] [Related]
3. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
[TBL] [Abstract][Full Text] [Related]
5. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
[TBL] [Abstract][Full Text] [Related]
6. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer.
McIntyre C; Byers S; Anson DS
J Gene Med; 2010 Sep; 12(9):717-28. PubMed ID: 20683858
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice.
Lau AA; Hannouche H; Rozaklis T; Hassiotis S; Hopwood JJ; Hemsley KM
Exp Neurol; 2010 Oct; 225(2):445-54. PubMed ID: 20673764
[TBL] [Abstract][Full Text] [Related]
8. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW
Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862
[TBL] [Abstract][Full Text] [Related]
9. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
[TBL] [Abstract][Full Text] [Related]
10. Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors.
Keriel A; René C; Galer C; Zabner J; Kremer EJ
J Virol; 2006 Feb; 80(3):1487-96. PubMed ID: 16415025
[TBL] [Abstract][Full Text] [Related]
11. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
Yogalingam G; Hopwood JJ
Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
[TBL] [Abstract][Full Text] [Related]
13. A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.
Winner LK; Beard H; Hassiotis S; Lau AA; Luck AJ; Hopwood JJ; Hemsley KM
Hum Gene Ther; 2016 May; 27(5):363-75. PubMed ID: 26975339
[TBL] [Abstract][Full Text] [Related]
14. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
Chen Y; Zheng S; Tecedor L; Davidson BL
Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
[TBL] [Abstract][Full Text] [Related]
17. An Engineered
Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
McIntyre C; Derrick Roberts AL; Ranieri E; Clements PR; Byers S; Anson DS
Mol Genet Metab; 2008 Apr; 93(4):411-8. PubMed ID: 18248829
[TBL] [Abstract][Full Text] [Related]
19. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
Perkins KJ; Muller V; Weber B; Hopwood JJ
Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
